Mounjaro
E135131
GIP receptor agonist
GLP-1 receptor agonist
antidiabetic drug
brand name drug
prescription medication
Mounjaro is a prescription medication (tirzepatide) used primarily to improve blood sugar control in adults with type 2 diabetes and increasingly known for its weight-loss effects.
All labels observed (3)
| Label | Occurrences |
|---|---|
| Mounjaro canonical | 3 |
| tirzepatide | 2 |
| weight-loss and diabetes drug Mounjaro | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T1168570 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Mounjaro Context triple: [Eli Lilly and Company, notableProduct, Mounjaro]
-
A.
Trulicity
Trulicity is a prescription GLP-1 receptor agonist medication used to improve blood sugar control in adults with type 2 diabetes.
-
B.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
C.
Denesuline
Denesuline are a First Nations people of the larger Dene cultural and linguistic group, traditionally inhabiting subarctic regions of northern Canada.
-
D.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
E.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Mounjaro Target entity description: Mounjaro is a prescription medication (tirzepatide) used primarily to improve blood sugar control in adults with type 2 diabetes and increasingly known for its weight-loss effects.
-
A.
Trulicity
Trulicity is a prescription GLP-1 receptor agonist medication used to improve blood sugar control in adults with type 2 diabetes.
-
B.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
C.
Denesuline
Denesuline are a First Nations people of the larger Dene cultural and linguistic group, traditionally inhabiting subarctic regions of northern Canada.
-
D.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
E.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
GIP receptor agonist
ⓘ
GLP-1 receptor agonist ⓘ antidiabetic drug ⓘ brand name drug ⓘ prescription medication ⓘ |
| administeredBy |
subcutaneous injection in abdomen
ⓘ
subcutaneous injection in thigh ⓘ subcutaneous injection in upper arm ⓘ |
| affects |
glucagon-like peptide-1 receptor
ⓘ
glucose-dependent insulinotropic polypeptide receptor ⓘ |
| approvalYear | 2022 ⓘ |
| approvedBy |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
| approvedFor | adults with type 2 diabetes mellitus ⓘ |
| boxedWarning | risk of thyroid C-cell tumors observed in rodents ⓘ |
| commonAdverseEffect |
constipation
ⓘ
decreased appetite ⓘ diarrhea ⓘ nausea ⓘ vomiting ⓘ |
| contraindicatedIn |
patients with multiple endocrine neoplasia syndrome type 2
ⓘ
patients with personal or family history of medullary thyroid carcinoma ⓘ |
| developedBy | Eli Lilly and Company ⓘ |
| dosageForm | solution for injection in prefilled pen ⓘ |
| dosingFrequency | once weekly ⓘ |
| effect |
promotes weight loss in many patients with type 2 diabetes
ⓘ
reduces HbA1c ⓘ |
| hasActiveIngredient |
Mounjaro
self-linksurface differs
ⓘ
surface form:
tirzepatide
|
| hasGenericName | tirzepatide ⓘ |
| hasHigherStrength |
10 mg once weekly
ⓘ
12.5 mg once weekly ⓘ 15 mg once weekly ⓘ 5 mg once weekly ⓘ 7.5 mg once weekly ⓘ |
| hasPharmacologicalClass | dual GIP and GLP-1 receptor agonist ⓘ |
| hasRouteOfAdministration | subcutaneous injection ⓘ |
| indicatedFor | type 2 diabetes mellitus ⓘ |
| mechanismOfAction |
enhances insulin secretion in a glucose-dependent manner
ⓘ
reduces appetite ⓘ reduces glucagon secretion ⓘ slows gastric emptying ⓘ |
| notIndicatedFor |
diabetic ketoacidosis
ⓘ
type 1 diabetes mellitus ⓘ |
| regulates | blood glucose levels ⓘ |
| seriousAdverseEffect |
acute kidney injury
ⓘ
gallbladder disease ⓘ pancreatitis ⓘ |
| startingDose | 2.5 mg once weekly ⓘ |
| usedFor |
improving glycemic control in adults with type 2 diabetes
ⓘ
weight loss ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Mounjaro Description of subject: Mounjaro is a prescription medication (tirzepatide) used primarily to improve blood sugar control in adults with type 2 diabetes and increasingly known for its weight-loss effects.
Referenced by (6)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
weight-loss and diabetes drug Mounjaro
this entity surface form:
tirzepatide
this entity surface form:
tirzepatide